In vitro activity of the new 4-quinolone compound RO 23-6240
- 1 April 1987
- journal article
- research article
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 6 (2), 161-164
- https://doi.org/10.1007/bf02018199
Abstract
The in vitro activity of the new 4-quinolone Ro 23-6240 was compared with that of pefloxacin, ciprofloxacin, norfloxacin, nalidixic acid and gentamicin against a total of 397 recent clinical isolates. An agar dilution procedure was used to determine MICs and two inocula (104 and 10 6 CFU)were used throughout. Ro 23-6240 inhibited most species of the Enterobacteriaceae, Haemophilus influenzae andStaphylococcus aureus (including methicillinresistant strains) at ⩽ 1 mg/l.Pseudomonas aeruginosa was somewhat more resistant (MIC 90 4 mg/l) and the Bacteroides fragilis group were considerably more resistant (MIC 90 32 mg/l). Overall Ro 23-6240 was as active as pefloxacin but was two-to eight-fold less active than ciprofloxacin against most species tested.This publication has 5 references indexed in Scilit:
- In vitro activity of Ro 23-6240, a new fluorinated 4-quinoloneAntimicrobial Agents and Chemotherapy, 1986
- In-vitro activity of pefloxacin compared to enoxacin, norfioxacin, gentamicin and newβ-lactamsJournal of Antimicrobial Chemotherapy, 1985
- In vitro activity of enoxacin, a quinolone carboxylic acid, compared with those of norfloxacin, new beta-lactams, aminoglycosides, and trimethoprimAntimicrobial Agents and Chemotherapy, 1983
- In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agentsAntimicrobial Agents and Chemotherapy, 1983
- In vitro antibacterial activity of norfloxacin (MK-0366)Antimicrobial Agents and Chemotherapy, 1982